Evidence map›Paper›PMID 25706094›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2015

Increased susceptibility of estrogen-induced bladder outlet obstruction in a novel mouse model.

Neville Ngai-Chung Tam, Xiang Zhang, Hong Xiao, Dan Song, Linda Levin, Jarek Meller, Shuk-Mei Ho

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. [Outcome of surgical management and pathogenesis of female primary bladder neck obstruction].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019
    Article
  7. Article
  8. In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood.Toxicological sciences : an official journal of the Society of Toxicology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Neville Ngai-Chung Tam1] Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] Center for Environmental Genetics, University of Cincinnati College of Medicine, Cincinnati, OH, USA [3] Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Xiang Zhang1] Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] Center for Environmental Genetics, University of Cincinnati College of Medicine, Cincinnati, OH, USA [3] Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Hong XiaoDepartment of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Dan SongDepartment of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Linda LevinDepartment of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Jarek Meller1] Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] Center for Environmental Genetics, University of Cincinnati College of Medicine, Cincinnati, OH, USA [3] Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Shuk-Mei Ho1] Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] Center for Environmental Genetics, University of Cincinnati College of Medicine, Cincinnati, OH, USA [3] Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA [4] Cincinnati Veteran Affairs Hospital Medical Center, Cincinnati, OH, USA.
University of Cincinnati Medical Center · USMedpace (United States) · USUniversity of Cincinnati · US

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI PINNEY, SUSAN MENGEL · 1992 to 2022
$35.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR026314 · NCRR · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E. · 2009 to 2011
$14.3M
Epigenetic Basis for Prostate Carcinogenesis following Early Estrogenic ExposuresR01ES015584 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HO, SHUK-MEI, PRINS, GAIL S · 2008 to 2012
$3.1M
Role of ubiquitylation in renal cancerR01CA122346 · NCI · UNIVERSITY OF CINCINNATI · PI CZYZYK-KRZESKA, MARIA F · 2007 to 2017
$3.0M
Susceptible Window of High Fat Diet/Bisphenol A Programming of Breast Cancer RiskU01ES019480 · NIEHS · UNIVERSITY OF CINCINNATI · PI HO, SHUK-MEI · 2010 to 2014
$2.2M
Effects of Arsenic on Human Prostate Stem Cells and Prostate Cancer RiskR01ES022071 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HO, SHUK-MEI, PRINS, GAIL S · 2012 to 2016
$1.9M
PROSTATIC DIFFERENTIATION &SEX HORMONE METABOLISMR01CA015776 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 1987 to 2008
$1.8M
Metallothionein &Cadmium Carcinogenesis in the ProstateR01CA062269 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 1995 to 2006
$1.4M
Hormone-induced inflammation and prostate cancerR01CA112532 · NCI · UNIVERSITY OF CINCINNATI · PI HO, SHUK-MEI · 2006 to 2009
$1.1M
Chronic exposure to Biphenol A and uterine cancer risk markersU01ES020988 · NIEHS · UNIVERSITY OF CINCINNATI · PI HO, SHUK-MEI · 2011 to 2014
$796k
Norovirus Capsid: a Novel Drug TargetR21AI097936 · NIAID · UNIVERSITY OF CINCINNATI · PI MELLER, JAREK · 2013 to 2014
$392k
Gene Methylation Targets for Prostate Cancer Prevention by Early Soy ExposureR21CA156042 · NCI · UNIVERSITY OF CINCINNATI · PI TAM, NGAI CHUNG NEVILLE · 2011 to 2012
$376k
BLRD VA 01BX000675BLRD VA I01 BX000675NCI NIH HHS R01 CA015776NCI NIH HHS R01CA015776NCI NIH HHS R01 CA062269NCI NIH HHS R01CA062269NCI NIH HHS R01 CA112532NCI NIH HHS R01CA112532NCI NIH HHS R01CA122346NCI NIH HHS R21CA156042NCRR NIH HHS UL1RR026314NIAID NIH HHS R21AI097936NIEHS NIH HHS P30ES006096NIEHS NIH HHS R01 ES015584NIEHS NIH HHS R01ES015584NIEHS NIH HHS R01ES022071NIEHS NIH HHS U01 ES019480NIEHS NIH HHS U01ES019480NIEHS NIH HHS U01ES020988
6 · The paper itself

Abstract

Disorders of the prostate and lower urinary tract are common in elderly men. We investigated the role of metallothionein-1 (MT1) in prostate carcinogenesis by generating a prostate-specific, MT1-expressing mouse. Unexpectedly, genomic analyses revealed that a 12.1-kb genomic region harboring several conserved noncoding elements was unintentionally deleted, upstream of the transgene integration site in the mouse, which we named it 12.1ΔMT1. Male 12.1ΔMT1 mice chronically treated with testosterone (T) plus 17β-estradiol (E2) to induce prostate cancer exhibited no evidence of precancerous or cancerous lesions. Instead, most of them exhibited a bladder outlet obstruction (BOO) phenotype not observed in treated wild-type (WT) mice. Thus, we hypothesized that 12.1ΔMT1 is a novel model for studying the hormonal requirement for BOO induction. Adult male 12.1ΔMT1 and WT mice were treated with T, E2, bisphenol A (BPA), T+E2, or T+BPA for up to 6 months. Histologic and immunohistochemical analysis of the prostate, bladder, and urethra were performed. No significant prostate pathologies were observed in WT or 12.1ΔMT1 mice treated with any of the hormone regimens. As expected, prostatic regression occurred in all E2-treated animals (WT and 12.1ΔMT1). Of great interest, despite a small prostate, 100% of E2-treated 12.1ΔMT1 mice, but only 40% of E2-treated WT mice, developed severe BOO (P<0.01). In contrast, T+E2 treatment was less effective than E2 treatment in inducing severe BOO in 12.1ΔMT1 mice (68%, P<0.05) and was completely ineffective in WT animals. Similarly, T, BPA, and T+BPA treatments did not induce BOO in either WT or 12.1ΔMT1 mice. The BOO pathology includes a thinner detrusor wall, narrowing of bladder neck and urethral lumen, and basal cell hyperplasia in the bladder body and urethra. These findings indicate that 12.1ΔMT1 mice exhibit enhanced susceptibility to E2-induced BOO that is independent of prostate enlargement but that is attenuated by the conjoint treatment with T.

Indexed as

AnimalsDisease Models, AnimalEstradiolFemaleGene DeletionHyperplasiaImmunohistochemistryMaleMetallothioneinMiceMice, TransgenicPhenotypeProstateReceptors, N-Methyl-D-AspartateUrethraUrinary BladderEstradiolMetallothioneinmetallothionein-1, mouseReceptors, N-Methyl-D-Aspartate

Identifiers

PMID25706094
OpenAlexW2071481944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.